Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axcella Health Inc. stock logo
AXLA
Axcella Health
$0.40
$0.84
$0.34
$41.25
$1.18M0.46267,009 shs6,782 shs
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
$1.14
-2.6%
$1.17
$0.72
$6.45
$11.41M0.22388,376 shs98,008 shs
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
$3.10
$4.66
$0.30
$1.47
$105.77M2.6993,510 shsN/A
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
$0.17
$0.03
$2.51
$5.04M0.939.20 million shs23.04 million shs
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$1.97
-0.8%
$3.12
$1.81
$26.96
$10.94M0.54133,066 shs380,089 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axcella Health Inc. stock logo
AXLA
Axcella Health
0.00%0.00%0.00%0.00%0.00%
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
0.00%+7.55%+1.79%-0.88%-77.80%
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
0.00%0.00%0.00%0.00%0.00%
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
0.00%0.00%0.00%0.00%0.00%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
0.00%+7.38%-51.36%-69.48%-88.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/AN/AN/AN/AN/AN/AN/AN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
4.1244 of 5 stars
3.54.00.04.70.60.80.6
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
N/AN/AN/AN/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
4.6742 of 5 stars
3.52.00.04.60.63.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axcella Health Inc. stock logo
AXLA
Axcella Health
0.00
N/AN/AN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
3.00
Buy$30.002,531.58% Upside
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
0.00
N/AN/AN/A
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
0.00
N/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.00
Buy$72.333,581.09% Upside

Current Analyst Ratings Breakdown

Latest BCLI, GMDA, XFOR, AXLA, and ERYP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1.50 ➝ $7.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/AN/AN/AN/A$1.42 per shareN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/A($1.36) per shareN/A
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
$32.66M3.24N/AN/A$0.80 per share3.88
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
$1.78M0.00N/AN/A($0.02) per share0.00
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$2.56M4.44N/AN/A$3.90 per share0.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axcella Health Inc. stock logo
AXLA
Axcella Health
-$81.19M-$19.25N/AN/AN/AN/A-259.91%N/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$11.62M-$3.36N/AN/AN/AN/AN/A-519.50%8/13/2025 (Estimated)
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
-$240KN/A0.00N/AN/AN/AN/AN/A
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
-$63M-$0.63N/AN/AN/AN/AN/A-57.59%N/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$37.45M$2.140.92N/AN/A46.54%-181.56%-54.36%8/6/2025 (Estimated)

Latest BCLI, GMDA, XFOR, AXLA, and ERYP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$0.38-$0.45-$0.07-$0.45N/AN/A
5/1/2025Q1 2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$4.13$0.04+$4.17$0.04$7.03 million$28.81 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/AN/AN/AN/AN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/AN/A
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
N/AN/AN/AN/AN/A
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
N/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/A
0.80
0.80
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/A
0.21
0.21
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
0.32
3.65
3.65
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
213.14
2.16
2.09
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.30
3.70
3.58

Institutional Ownership

CompanyInstitutional Ownership
Axcella Health Inc. stock logo
AXLA
Axcella Health
65.07%
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
14.33%
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
1.09%
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
50.34%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
72.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axcella Health Inc. stock logo
AXLA
Axcella Health
112.95 million2.88 millionOptionable
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
409.84 million8.74 millionOptionable
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
4934.12 million33.46 millionNot Optionable
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
143154.05 million143.70 millionOptionable
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
805.79 million5.65 millionOptionable

Recent News About These Companies

X4 Pharmaceuticals, Inc. (XFOR) - Yahoo Finance
X4 Pharmaceuticals Inc News (XFOR) - Investing.com
XFOR X4 Pharmaceuticals, Inc. - Seeking Alpha
X4 Pharmaceuticals Analyst Ratings
Earnings Preview For X4 Pharmaceuticals
Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Axcella Health stock logo

Axcella Health NASDAQ:AXLA

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Brainstorm Cell Therapeutics stock logo

Brainstorm Cell Therapeutics NASDAQ:BCLI

$1.14 -0.03 (-2.56%)
Closing price 07/3/2025 03:55 PM Eastern
Extended Trading
$1.15 +0.01 (+1.23%)
As of 07/3/2025 04:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

ERYTECH Pharma stock logo

ERYTECH Pharma NASDAQ:ERYP

ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Gamida Cell stock logo

Gamida Cell NASDAQ:GMDA

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.

X4 Pharmaceuticals stock logo

X4 Pharmaceuticals NASDAQ:XFOR

$1.96 -0.02 (-0.76%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$1.92 -0.05 (-2.29%)
As of 07/3/2025 04:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.